The serine protease inhibitor camostat mesylate, approved in Japan to treat diseases, has been shown to block TMPRSS2 activity and is thus an interesting candidate to treat COVID-19 patients with pre-existing CAD [31, 32]. The gene discussed is TMPRSS2; the disease is coronary artery disorder.